Targeting Lysine α-Ketoglutarate Reductase to Treat Pyridoxine-Dependent Epilepsy

Area of Science:

• Biochemistry
• Genetics
• Neuroscience

Background:

• Pyridoxine-dependent epilepsy (PDE) is a rare metabolic disorder caused by ALDH7A1 gene mutations affecting lysine metabolism.
• While pyridoxine controls seizures, most PDE patients experience intellectual disabilities.

Purpose of the Study:

• To investigate substrate reduction therapy for PDE by targeting lysine α-ketoglutarate reductase (LKR).
• To assess the efficacy of LKR inhibition in ameliorating PDE-related neurological deficits in a mouse model.

Main Methods:

• Genetic perturbation of the lysine α-ketoglutarate reductase (LKR) enzyme in ALDH7A1-deficient mice.
• Evaluation of toxic metabolite accumulation, seizure activity, brain development, and cognitive function.

Main Results:

• A homozygous LKR mutation eliminated toxic lysine catabolism intermediates.
• The LKR mutation abolished seizures and restored normal brain development and cognitive function in the mice.
• These findings validate LKR as a therapeutic target for PDE.

Conclusions:

• Genetic inhibition of LKR demonstrates the effectiveness of substrate reduction therapy for PDE.
• This approach successfully reverses neurological impairments associated with ALDH7A1 deficiency.
• LKR inhibition presents a promising therapeutic strategy for pyridoxine-dependent epilepsy.